Hydroxychloroquine serum concentration in coronavirus disease 2019 (COVID-19) patients: a retrospective study

Algeria has adopted a therapeutic protocol using hydroxychloroquine (HCQ) as a first-line treatment for patients with coronavirus disease 2019 (COVID-19). The administration of HCQ must be accompanied by appropriate cardiac and therapeutic pharmacological monitoring to avoid side effects and toxicit...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Saadi Fatima Zohra, Lachgueur Nassima
Formato:	article
Lenguaje:	EN
Publicado:	Taylor & Francis Group 2021
Materias:	forensic sciences concentration covid-2019 hydroxychloroquine hplc-dad plasma Criminal law and procedure K5000-5582 Public aspects of medicine RA1-1270
Acceso en línea:	https://doaj.org/article/5e98189a6c5c4b79bdb421a4ea9277f0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5e98189a6c5c4b79bdb421a4ea9277f0
record_format	dspace
spelling	oai:doaj.org-article:5e98189a6c5c4b79bdb421a4ea9277f02021-12-01T14:40:59ZHydroxychloroquine serum concentration in coronavirus disease 2019 (COVID-19) patients: a retrospective study2096-17902471-141110.1080/20961790.2021.1936896https://doaj.org/article/5e98189a6c5c4b79bdb421a4ea9277f02021-07-01T00:00:00Zhttp://dx.doi.org/10.1080/20961790.2021.1936896https://doaj.org/toc/2096-1790https://doaj.org/toc/2471-1411Algeria has adopted a therapeutic protocol using hydroxychloroquine (HCQ) as a first-line treatment for patients with coronavirus disease 2019 (COVID-19). The administration of HCQ must be accompanied by appropriate cardiac and therapeutic pharmacological monitoring to avoid side effects and toxicity. This work is a retrospective descriptive study aiming to estimate the HCQ levels of COVID-19 patients. HCQ concentrations in blood samples from COVID-19 patients were determined using high performance liquid chromatography with diode array detector (HPLC-DAD) after liquid-liquid extraction of plasma. The coefficient of determination (r2) of this method was 0.9999. The limits of quantification and detection were 0.05 mg/L and 0.02 mg/L, respectively, with coefficients of variance less than 6%. Patient monitoring was performed following recommendations for the therapeutic pharmacological monitoring of HCQ in patients treated for SARS-CoV-2 (COVID-19) infection validated by the coordinated action (AC43) of the National Agency for Research on AIDS and Viral Hepatitis (ANRS) and Therapeutic Pharmacological Monitoring and Personalization of Treatments (STP-PT) group. A total of 267 blood samples from 240 patients were analyzed, 49% for males and 51% for females. More than a third of the patients were 60–80 years old. The majority (68%) of the HCQ concentrations were between 0.1 and 1 mg/L. Additionally, more than 20% were between 0.05 and 0.1 mg/L, while only 7.5% were less than 0.05mg/L and 1.5% were greater than 1 mg/L. In summary, patients with COVID-19 showed a good tolerance to HCQ in the majority of cases.Key Points HCQ was proposed to be a promised treatment for COVID-19. A reverse phase HPLC-DAD method was validated for HCQ concentration determination in plasma. Patients hospitalized for COVID-19 were monitored according to the guideline established by the French National Team AC43 of the ANRS and the STP-PT group. Patients showed a very good tolerance to HCQ with no observed cases of toxicity.Saadi Fatima ZohraLachgueur NassimaTaylor & Francis Grouparticleforensic sciencesconcentrationcovid-2019hydroxychloroquinehplc-dadplasmaCriminal law and procedureK5000-5582Public aspects of medicineRA1-1270ENForensic Sciences Research, Vol 6, Iss 3, Pp 215-217 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	forensic sciences concentration covid-2019 hydroxychloroquine hplc-dad plasma Criminal law and procedure K5000-5582 Public aspects of medicine RA1-1270
spellingShingle	forensic sciences concentration covid-2019 hydroxychloroquine hplc-dad plasma Criminal law and procedure K5000-5582 Public aspects of medicine RA1-1270 Saadi Fatima Zohra Lachgueur Nassima Hydroxychloroquine serum concentration in coronavirus disease 2019 (COVID-19) patients: a retrospective study
description	Algeria has adopted a therapeutic protocol using hydroxychloroquine (HCQ) as a first-line treatment for patients with coronavirus disease 2019 (COVID-19). The administration of HCQ must be accompanied by appropriate cardiac and therapeutic pharmacological monitoring to avoid side effects and toxicity. This work is a retrospective descriptive study aiming to estimate the HCQ levels of COVID-19 patients. HCQ concentrations in blood samples from COVID-19 patients were determined using high performance liquid chromatography with diode array detector (HPLC-DAD) after liquid-liquid extraction of plasma. The coefficient of determination (r2) of this method was 0.9999. The limits of quantification and detection were 0.05 mg/L and 0.02 mg/L, respectively, with coefficients of variance less than 6%. Patient monitoring was performed following recommendations for the therapeutic pharmacological monitoring of HCQ in patients treated for SARS-CoV-2 (COVID-19) infection validated by the coordinated action (AC43) of the National Agency for Research on AIDS and Viral Hepatitis (ANRS) and Therapeutic Pharmacological Monitoring and Personalization of Treatments (STP-PT) group. A total of 267 blood samples from 240 patients were analyzed, 49% for males and 51% for females. More than a third of the patients were 60–80 years old. The majority (68%) of the HCQ concentrations were between 0.1 and 1 mg/L. Additionally, more than 20% were between 0.05 and 0.1 mg/L, while only 7.5% were less than 0.05mg/L and 1.5% were greater than 1 mg/L. In summary, patients with COVID-19 showed a good tolerance to HCQ in the majority of cases.Key Points HCQ was proposed to be a promised treatment for COVID-19. A reverse phase HPLC-DAD method was validated for HCQ concentration determination in plasma. Patients hospitalized for COVID-19 were monitored according to the guideline established by the French National Team AC43 of the ANRS and the STP-PT group. Patients showed a very good tolerance to HCQ with no observed cases of toxicity.
format	article
author	Saadi Fatima Zohra Lachgueur Nassima
author_facet	Saadi Fatima Zohra Lachgueur Nassima
author_sort	Saadi Fatima Zohra
title	Hydroxychloroquine serum concentration in coronavirus disease 2019 (COVID-19) patients: a retrospective study
title_short	Hydroxychloroquine serum concentration in coronavirus disease 2019 (COVID-19) patients: a retrospective study
title_full	Hydroxychloroquine serum concentration in coronavirus disease 2019 (COVID-19) patients: a retrospective study
title_fullStr	Hydroxychloroquine serum concentration in coronavirus disease 2019 (COVID-19) patients: a retrospective study
title_full_unstemmed	Hydroxychloroquine serum concentration in coronavirus disease 2019 (COVID-19) patients: a retrospective study
title_sort	hydroxychloroquine serum concentration in coronavirus disease 2019 (covid-19) patients: a retrospective study
publisher	Taylor & Francis Group
publishDate	2021
url	https://doaj.org/article/5e98189a6c5c4b79bdb421a4ea9277f0
work_keys_str_mv	AT saadifatimazohra hydroxychloroquineserumconcentrationincoronavirusdisease2019covid19patientsaretrospectivestudy AT lachgueurnassima hydroxychloroquineserumconcentrationincoronavirusdisease2019covid19patientsaretrospectivestudy
_version_	1718404994227503104

Hydroxychloroquine serum concentration in coronavirus disease 2019 (COVID-19) patients: a retrospective study

Ejemplares similares